AP724A - Treatment of ovarian estrogen dependent conditions. - Google Patents

Treatment of ovarian estrogen dependent conditions. Download PDF

Info

Publication number
AP724A
AP724A APAP/P/1996/000840A AP9600840A AP724A AP 724 A AP724 A AP 724A AP 9600840 A AP9600840 A AP 9600840A AP 724 A AP724 A AP 724A
Authority
AP
ARIPO
Prior art keywords
antiprogestin
analog
administration
treatment
releasing hormone
Prior art date
Application number
APAP/P/1996/000840A
Other languages
English (en)
Other versions
AP9600840A0 (en
Inventor
Gary D Hodgen
Robert F Williams
Daniel Grow
Original Assignee
The Medical College Of Hampton Roads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medical College Of Hampton Roads filed Critical The Medical College Of Hampton Roads
Publication of AP9600840A0 publication Critical patent/AP9600840A0/xx
Application granted granted Critical
Publication of AP724A publication Critical patent/AP724A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
APAP/P/1996/000840A 1994-02-04 1995-02-02 Treatment of ovarian estrogen dependent conditions. AP724A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/191,631 US5681817A (en) 1994-02-04 1994-02-04 Treatment of ovarian estrogen dependent conditions
PCT/US1995/001479 WO1995020972A1 (en) 1994-02-04 1995-02-02 Treatment of ovarian estrogen dependent conditions

Publications (2)

Publication Number Publication Date
AP9600840A0 AP9600840A0 (en) 1996-07-31
AP724A true AP724A (en) 1999-01-18

Family

ID=22706258

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1996/000840A AP724A (en) 1994-02-04 1995-02-02 Treatment of ovarian estrogen dependent conditions.

Country Status (29)

Country Link
US (1) US5681817A (ru)
EP (1) EP0785792B1 (ru)
JP (1) JP3130048B2 (ru)
KR (1) KR970700507A (ru)
CN (1) CN1144486A (ru)
AP (1) AP724A (ru)
AT (1) ATE179610T1 (ru)
AU (1) AU689229B2 (ru)
BG (1) BG62238B1 (ru)
BR (1) BR9506606A (ru)
CA (1) CA2182183C (ru)
CZ (1) CZ291709B6 (ru)
DE (1) DE69509544T2 (ru)
DK (1) DK0785792T3 (ru)
ES (1) ES2132645T3 (ru)
FI (1) FI963036L (ru)
GR (1) GR3030164T3 (ru)
HU (1) HUT74622A (ru)
LT (1) LT4182B (ru)
LV (1) LV11782B (ru)
MD (1) MD1432C2 (ru)
NZ (1) NZ281441A (ru)
OA (1) OA10777A (ru)
PL (1) PL178273B1 (ru)
RO (1) RO117420B1 (ru)
RU (1) RU2110274C1 (ru)
SK (1) SK96296A3 (ru)
TJ (1) TJ242B (ru)
WO (1) WO1995020972A1 (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9700574A (es) * 1994-07-22 1997-12-31 Hampton Roads Medical College Metodo para establecer la secrecion de estrogeno tonico ovarico para regimenes terapeuticos prolongados.
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
AU9462498A (en) 1997-10-17 1999-05-10 Mochida Pharmaceutical Co., Ltd. Hysteromyoma remedy containing dienogest as the active ingredient
US6703367B1 (en) 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6355648B1 (en) * 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6417214B1 (en) * 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
DE60036723T2 (de) * 1999-08-31 2008-07-17 Bayer Schering Pharma Aktiengesellschaft Mesoprogestine zur behandlung und vorbeugung von hormonabhängigen gutartigen gynekologischen störungen
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CA2427731A1 (en) * 2000-10-30 2002-05-10 University Of Zurich Gnrh analogues for treatment of urinary incontinence
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US6960337B2 (en) * 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
JP4992091B2 (ja) * 2005-02-17 2012-08-08 ハダシット メディカル リサーチ サービシーズ アンド デベロップメント リミテッド 子宮内膜症を治療するためのビスホスホネート
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
TWI455716B (zh) * 2006-10-24 2014-10-11 Repros Therapeutics Inc 選擇性黃體激素受體調節劑用於製造治療雌激素依賴性病症之藥物的用途
ES2643318T3 (es) 2006-10-24 2017-11-22 Repros Therapeutics Inc. Composiciones y métodos para suprimir la proliferación endometrial
WO2008144143A1 (en) * 2007-05-14 2008-11-27 Drugtech Corporation Endometriosis treatment
ES2467942T3 (es) * 2007-09-20 2014-06-13 Lapidot Medical Import And Marketing Ltd Composiciones y medios para tratar leiomiomas uterinos, leiomioma, mioma, fibroides uterinos, endometriosis, adenomiosis y trastornos relacionados por mifepristona.
RU2359684C1 (ru) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения эндометриоза
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3560555A1 (en) 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE19975054I2 (de) 1987-08-08 2000-04-13 Akzo Nobel Nv Kontrazeptives Implantat
DE3744054A1 (de) 1987-12-21 1989-06-29 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DK0472725T3 (da) 1990-03-16 1997-11-03 Applied Research Systems Behandling af polycystisk ovariesygdom
US6827050B2 (en) 2001-12-21 2004-12-07 Caterpillar Inc Fluid control valve actuating system
US7283632B2 (en) 2003-09-09 2007-10-16 The Boeing Company Unauthorized access embedded software protection system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, Vol. 66, No. 3, issued 1992, V.G. GARZO et al., "Effects of and Antiprogesterone (ru486) on the Hypothalamic-Hypophyseal-Ovarian-Endometrial Axis During Luteal Phase of the Menstrual Cylce", pages 508-517 *

Also Published As

Publication number Publication date
WO1995020972A1 (en) 1995-08-10
ATE179610T1 (de) 1999-05-15
EP0785792A4 (ru) 1997-07-30
CA2182183C (en) 2003-09-16
AP9600840A0 (en) 1996-07-31
RU2110274C1 (ru) 1998-05-10
BR9506606A (pt) 1997-09-09
HUT74622A (en) 1997-01-28
TJ242B (en) 1999-11-24
OA10777A (en) 2002-12-23
CZ210396A3 (en) 1997-05-14
AU689229B2 (en) 1998-03-26
AU1838695A (en) 1995-08-21
MD1432C2 (ru) 2000-09-30
EP0785792A1 (en) 1997-07-30
ES2132645T3 (es) 1999-08-16
FI963036A0 (fi) 1996-08-01
FI963036A7 (fi) 1996-08-01
US5681817A (en) 1997-10-28
LV11782A (lv) 1997-06-20
DE69509544T2 (de) 1999-09-02
PL315792A1 (en) 1996-12-09
JPH09508418A (ja) 1997-08-26
PL178273B1 (pl) 2000-03-31
EP0785792B1 (en) 1999-05-06
NZ281441A (en) 1999-09-29
FI963036L (fi) 1996-08-01
MD1432B2 (en) 2000-03-31
LT96133A (en) 1997-01-27
DE69509544D1 (de) 1999-06-10
LV11782B (en) 1997-12-20
BG62238B1 (bg) 1999-06-30
KR970700507A (ko) 1997-02-12
DK0785792T3 (da) 1999-10-18
LT4182B (en) 1997-06-25
CA2182183A1 (en) 1995-08-10
GR3030164T3 (en) 1999-08-31
CZ291709B6 (cs) 2003-05-14
SK96296A3 (en) 1997-07-09
JP3130048B2 (ja) 2001-01-31
BG100766A (bg) 1997-06-30
RO117420B1 (ro) 2002-03-29
HU9601969D0 (en) 1996-09-30
CN1144486A (zh) 1997-03-05

Similar Documents

Publication Publication Date Title
AP724A (en) Treatment of ovarian estrogen dependent conditions.
US5468736A (en) Hormone replacement therapy
Felberbaum et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
Broekmans GnRH agonists and uterine leiomyomas
Friedman Treatment of uterine myomas with GnRH agonists
RU2181598C2 (ru) Восстановление тонической секреции эстрогена из яичников для продолжительных схем лечения
LT4341B (lt) Toninės kiaušidžių estrogeno sekrecijos sureguliavimas pailgintiems terapiniams režimams
Bromer et al. Medical treatment options for leiomyomas
Monroe et al. Clinical investigations of the contraceptive and therapeutic potential of nafarelin